BIETTI CRYSTALLINE DYSTROPHY
Clinical trials for BIETTI CRYSTALLINE DYSTROPHY explained in plain language.
Never miss a new study
Get alerted when new BIETTI CRYSTALLINE DYSTROPHY trials appear
Sign up with your email to follow new studies for BIETTI CRYSTALLINE DYSTROPHY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Gene therapy injection aims to restore sight in rare eye disease
Disease control OngoingThis study tests a single injection of ZVS101e gene therapy for people with Bietti's crystalline dystrophy, a rare inherited condition that leads to progressive vision loss. The therapy delivers a working copy of the CYP4V2 gene directly to the retina. Researchers will measure wh…
Matched conditions: BIETTI CRYSTALLINE DYSTROPHY
Phase: PHASE3 • Sponsor: Chigenovo Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Gene therapy injection aims to halt blindness from rare eye disorder
Disease control OngoingThis Phase 3 trial tests a gene therapy called VGR-R01 for Bietti crystalline dystrophy, a rare inherited condition that leads to progressive vision loss. The study will enroll 45 adults who receive either the gene therapy injection under the retina or a control treatment. Resear…
Matched conditions: BIETTI CRYSTALLINE DYSTROPHY
Phase: PHASE3 • Sponsor: Shanghai Vitalgen BioPharma Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
Gene therapy trial aims to halt blindness from rare crystal disease
Disease control OngoingThis early-stage trial tests a gene therapy called VGR-R01 for Bietti Crystalline Dystrophy, a rare inherited eye disease that leads to progressive vision loss. The study involves 12 adults who receive the therapy via injection into the eye. The main goal is to check safety and t…
Matched conditions: BIETTI CRYSTALLINE DYSTROPHY
Phase: PHASE1 • Sponsor: Shanghai Vitalgen BioPharma Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC